Below you can find prescribing guidelines and their review dates.
Principles of shared care protocols and guidelines
Acromegaly - Review date on publication of NICE guidance
Amiodarone - Review date January 2021
Azathioprine and Mercaptopurine in adults and young people over 16 years - July 2022
Bipolar disorder - February 2023
Dalteparin - June 2021
Dementia - Prescribing of Cognitive Enhancers - April 2022
Denosumab (Prolia ®▼) - October 2022
DMARDs monitoring quick reference guide - February 2022
Please refer to individual shared care guidelines for more detailed information
Epilepsy in adults - February 2021
Epilepsy in children - September 2021
Growth hormone: The treatment of Adults with Growth Hormone (Somatropin) - March 2021
Growth hormone - Treatment of children with recombinant human growth hormone - February 2025
Hydroxycarbamide - To be reviewed and retired January 2021. Note - if prescribing is being directed back to secondary care, please retain hydroxycarbamide as a specialist issued drug within the patients records so you are alerted to drug/disease interactions
Hydroxychloroquine - September 2021
Hypertension – Community Pharmacy Led Hypertension Service - January 2022
Leflunomide - October 2025
Melatonin in the treatment of sleep disorders in children - September 2025
Methotrexate - May 2021
Modafinil – February 2025
Mycophenolate - January 2020
Nebulised Colomycin® and tobramycin in adults with non-cystic fibrosis bronchiectasis - July 2021
Parkinson’s disease - November 2016
Prostatic Cancer - Hormonal Management of Prostatic Cancer – January 2021
Rifaxamin for Hepatic Encephalopathy - January 2020
Riluzole - August 2025
Sulfasalazine - Review date extended to November 2022
SSRIs in children and young people - June 2025
Triptorelin for the treatment of Central Precocious Puberty in Children - February 2025